Mark Goodman, PhD, earns nuclear medicine imaging award
Woodruff Health Sciences Center | June 1, 2012
Mark Goodman, PhD, professor and Endowed Chair in Imaging Science at Emory University School of Medicine's Department of Radiology and Imaging Sciences, has been awarded the Paul C. Aebersold Award for Outstanding Achievement in Basic Science applied to Nuclear Medicine. Goodman, who is a member of the Winship Cancer Institute of Emory University, is also a program director in the Emory Center for Systems Imaging, professor of hematology and oncology and psychiatry and behavioral sciences.
Each year the Society of Nuclear Medicine Committee on Awards selects an individual as the recipient of this award, which honors outstanding achievement in basic science applied to nuclear medicine. It is named for Paul C. Aebersold, a pioneer in the biologic and medical application of radioactive materials and the first director of the Atomic Energy Commission's Division of Isotopes Development at Oak Ridge. Dr. Goodman will be honored June 10th at a reception during the Society of Nuclear Medicine's annual meeting.
"We are thrilled to learn of this prestigious award for Dr. Goodman," says Carolyn Meltzer, MD, chair of the Department of Radiology and Imaging Sciences. "He is indeed a visionary in the field of nuclear and molecular imaging. His ability to build strong teams of researchers from various disciplines is a testament to his focus on collaboration and results. He is a wonderful role model to young and established faculty alike."
Goodman joined Emory in 1993 to establish the PET radiopharmaceutical research program. Dr. Goodman is one of a select group of researchers in the United States who has developed novel imaging biomarkers and has seen their development through to clinical trials. Dr. Goodman's research interests encompass PET and single photon emission computed tomography radiotracer development in oncology, brain and heart agents. His research has resulted in the translation of the first reported synthetic amino alicyclic acid radiolabeled with the PET for imaging both intracranial tumors and prostate cancer in patients. In applied research, Dr. Goodman's interests include the development of automated devices to facilitate the use of new radiotracers in clinical medicine.